X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

MedComm

期刊標題檢索 最新評論: A very promising new journal, the next big thing for sure, with many s... (2024-03-31)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[MedComm]您好,您是該頁面的第 34860 位訪客。

期刊簡介
期刊名稱MedComm MedComm

(According to the latest JCR data, this journal is not indexed in the JCR.)
LetPub Score
8.2
50 ratings
Rate

Reputation
8.0

Influence
8.3

Speed
7.7

期刊簡稱
ISSN2688-2663
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
6.701.9261.373
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q2104 / 404
Category: Medicine
Subcategory: Genetics (clinical)
Q227 / 99
Category: Medicine
Subcategory: Biochemistry (medical)
Q220 / 72
Category: Medicine
Subcategory: Genetics
Q2105 / 347
Category: Medicine
Subcategory: Drug Discovery
Q251 / 157
Category: Medicine
Subcategory: Immunology and Allergy
Q287 / 233
Category: Medicine
Subcategory: Cell Biology
Q2133 / 285

自引率 (2023-2024)3.70%自引率趨勢
掲載範囲
MedComm is a peer-reviewed, online open access journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged. MedComm is interested in topics including but not limited to clinical medicine, molecule diagnostics, epigenetics/genetics, cell biology, drug discovery, evolutionary medicine, nanotechnology and artificial intelligence. The journal focuses on clinical and experimental advances on disease characteristics, pathogenic mechanism and medical techniques.

MedComm是同行评审的在线开放获取期刊,及时发表具有新颖性的、对人类健康有重要意义的开创性医学研究。该期刊重视原创性发现,旨在促进对发病机制的理解及改善对人类疾病的诊断与治疗,尤其青睐利用分子生物学、细胞生物学、化学、药理学或材料科学方法解决临床、基础和转化医学问题的跨学科研究。MedComm关注的主题包括但不限于临床医学、分子诊断、表观遗传学/遗传学、细胞生物学、药物发现、进化医学、纳米技术和人工智能。该期刊聚焦疾病特征、致病机制和医学技术的临床与实验进展。
官方網站https://onlinelibrary.wiley.com/journal/26882663
在線稿件提交https://mc.manuscriptcentral.com/medcomm
開放訪問Yes
出版商Wiley
主題領域MEDICINE, RESEARCH & EXPERIMENTAL
出版國/地區Australia
發行頻率四半期刊行
創刊年2020
每年文章數201每年文章數趨勢
黃金OA百分比81.39%
OA Related Info
APC: Yes( USD3500; GBP2550; EUR3050; )
APC waiver:Check Notes
Other charges: No
Keywords: biomedicine、clinical medicine、disease treatment、drug discovery、pathogenesis
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
MEDICINE, RESEARCH & EXPERIMENTALESCIQ111/189
索引 (SCI or SCIE)
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2688-2663%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 10 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【MedComm】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    NATURE REVIEWS DRUG DISCOVERYH-index: 289

    CiteScore: 137.40
    LANCETH-index: 700

    CiteScore: 148.10
    NEW ENGLAND JOURNAL OF MEDICINEH-index: 933

    CiteScore: 145.40
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    Nature Reviews Disease PrimersH-index: 48

    CiteScore: 76.70
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    NATURE REVIEWS IMMUNOLOGYH-index: 351

    CiteScore: 93.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONH-index: 622

    CiteScore: 48.20
    World PsychiatryH-index: 70

    CiteScore: 64.10
    學科內最受檢索的期刊 頁面查看次數
    MEDICINE640960
    BIOMATERIALS574662
    BIOMEDICINE & PHARMACOTHERAPY498368
    Frontiers in Pharmacology487323
    JOURNAL OF ETHNOPHARMACOLOGY479393
    Journal of Materials Chemistry B476066
    Frontiers in Immunology458032
    COLLOIDS AND SURFACES B-BIOINTERFACES419246
    COMPUTERS IN BIOLOGY AND MEDICINE416597
    Frontiers in Oncology413507
  •  

    MedComm MedComm
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [MedComm] 的評論撰寫評論
作者: gefche


領域: 生物学
審稿時間: 3.0 month(s)
結果: 修改後接受


撰寫評論

2024-03-31 04:58:52 評論於
A very promising new journal, the next big thing for sure, with many spin-off series as well. However, the current pace is incredibly slow, almost unsustainable for the average person
(0) 讚! | gefche

作者: 扎根科研


領域: 医学
審稿時間: 4.0 month(s)
結果: 修改後接受


撰寫評論

2023-10-13 12:07:23 評論於
The external audit requirements are quite high. The first major revision had four reviewers, two major revisions, and two minor revisions. The reviewers all felt responsible and raised a lot of questions, nearly 40+. The second minor revision had two reviewers (probably the ones who reviewed the two major revisions before), who still raised many questions and requested the minor revision. The third minor revision was sent to one of the reviewers again, and the editor-in-chief also made some suggestions. The fourth time, it was finally accepted (pre-accepted only), but a careful check and revision of the final version still need to be submitted. Then it's signing the copyright agreement, paying the page fee, proofreading before publication...

Although it is a new journal, the initial IF is close to 10, destined to be a 10+ or even 20+ magazine in the future. Checking, I found that this journal is a sister publication of Signal Transduction and Targeted Therapy, with the same editor-in-chief. It will also follow the development model of STTT in the future, with unlimited potential. Overall, the quality of this journal is quite high at the moment, and its future development potential should be good too. It is also because of these reasons that some big names are submitting papers...I was also introduced by a classmate from a big-shot's research group to try it out first, haha
(1) 讚! | 扎根科研

作者: 扎根科研


領域: 医学
審稿時間: 4.0 month(s)
結果: 修改後接受


撰寫評論

2023-10-13 12:03:42 評論於
Here, I briefly share my submission process:
Submitted on April 7th, undergoing initial checking;
Around April 15th, sent for external review, under review status;
May 20th, initial review completed, received Major revision decision;
June 11th, revised, undergoing initial checking status;
June 27th, second review completed, received Minor revision decision;
July 8th, revised, undergoing initial checking status;
July 21st, third review completed, received another Minor revision decision;
July 25th, revised, undergoing initial checking status;
July 30th, finally received Acceptance email, but it's only provisional, still need to revise and submit final version;
August 5th, received acceptance for final version email
(208) 讚! | 扎根科研

作者: Levy


領域: 生物学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2022-04-07 23:48:44 評論於
No impact factor, low cost-effectiveness.
(5) 讚! | Levy

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [MedComm] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*